Jun. 17 at 9:52 PM
$SABS
Quote seekingalpha article
The Phase 3 trials in China have been a huge success. Rademikibart did not only meet its goals; it generated numbers that suggested that it could be better than the current market leader, Dupixent. In dermatology trials, eczema improvements are measured by the EASI score. By week 52, 96.6% of patients on rademikibart achieved EASI-75, which is huge compared to Dupixent, where only 65% of patients achieved EASI-75 at 52 weeks. EASI-90 was achieved by 85.3% of patients who achieved a 90% reduction in their eczema, an exceptionally high bar for a chronic autoimmune disease. For comparison, Dupixent achieved a score of 51% at 52 weeks.”
